Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2001 May;50(2):87–92. doi: 10.1007/s002620100171

Active idiotypic vaccination in a patient with biclonal follicular lymphoma

Yvelise Barrios 1, Aresio Plaza 1, Rafael Cabrera 2, Rosa Yáñez 1, Eduardo Suárez 1, Manuel Nicolás Fernández 2, Fernando Díaz-Espada 1
PMCID: PMC11036824  PMID: 11401030

Abstract

Specific immunological responses to the idiotypic epitopes present in the surface immunoglobulin (Ig) of the clonal tumour population can be induced for active immunotherapy in patients with B-cell non-Hodgkin lymphoma (NHL). The clonality of the tumour cells should have important implications for the success of the implemented therapy. Here we report on the case of a patient enrolled in a protocol of active idiotypic immunotherapy in which previous cytofluorometric analysis showed a major IgM+, κp+ population in the tumoral cell suspensions. However, sequence analysis of both tumour sample and tumour-derived hybrids revealed the presence of two unrelated clones that used different VH and VK gene segments. It was possible to obtain hybridomas secreting these two different IgM, κp idiotypic proteins. The patient was immunised with a mixture of these two idiotypic Igs conjugated to keyhole limpet haemocyanin. Anti-idiotypic antibodies directed against both tumour-associated proteins were detected. This is the first case of anti-idiotypic therapy in a patient with a biclonal NHL. Our work calls attention to the question of clonality in the context of idiotypic vaccination in NHL patients.

Keywords: Key words Biclonal lymphoma, Idiotypic immunotherapy, Tumour vaccines

Footnotes

Received: 18 May 2000 / Accepted: 13 December 2000


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES